## Timing of PCR and Antibody Testing in Patients with COVID-19 associated dermatologic manifestations

**Authors:** Esther E. Freeman MD PhD,<sup>1,2</sup> Devon E. McMahon BA,<sup>3</sup> Lindy P. Fox MD,<sup>2</sup> Marlys S. Fassett MD PhD<sup>3,4</sup>

<sup>1</sup>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; <sup>2</sup>Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Department of Dermatology, University of California San Francisco, San Francisco, CA; <sup>4</sup>Department of Immunology and Microbiology, University of California San Francisco, San Francisco, CA

## **Corresponding Author:**

Esther Freeman, MD, PhD

Massachusetts General Hospital

55 Fruit St, Boston, MA 02114

Email: efreeman@mgh.harvard.edu

Keywords: COVID-19; SARS-CoV-2; dermatology; public health; registry; pernio; chilblains

Funding: None

**Disclosures:** Drs. Freeman and Fox are part of the American Academy of Dermatology (AAD) COVID-19 Ad Hoc Task Force.

**Ethics:** The registry was reviewed by the Partners Healthcare (MGH) Institutional Review Board (IRB) and was determined to not meet the definition of Human Subjects Research.

## Manuscript Text

A recent study from France noted 40 patients with chilblain-like lesions in suspected COVID-19.<sup>1</sup> None tested PCR positive for SARS-CoV-2, but 30% had detectable antibodies. The rapid increase in chilblain/pernio-like cases during the COVID-19 pandemic is likely SARS-CoV-2-associated. The relationship between skin symptom onset and COVID-19 PCR/antibody test timing, however, remains uncharacterized.

We established an international registry for cutaneous manifestations of COVID-19.<sup>2, 3</sup> Providers reported time between dermatologic symptom onset and positive/negative COVID-19 laboratory results, when available.

From 8 April-30 June, 2020, 906 laboratory-confirmed or suspected COVID-19 cases with dermatologic manifestations were reported, 534 of which were chilblains/pernio.<sup>3</sup> Among PCR-tested patients, 57%(n=208) overall and 15%(n=23) of chilblains/pernio cases were PCR-positive. Antibody positivity was 37%(n=39) overall and 19%(n=15) for chilblains/pernio.

We evaluated 163 patients with timing information on PCR and/or antibody testing (Table 1). For patients with suspected COVID-19 and any cutaneous manifestation, PCR-positive testing occurred median 6 (IQR 1-14) days after dermatologic symptoms started while PCR-negative testing occurred median 14 (IQR 7-24) days later. For patients with pernio/chilblains, PCR-positivity was noted 8 (IQR 5-14) days after symptoms and negativity median 14 (IQR 7-28) days later. Antibody testing (IgM or IgG) was positive median 30 (IQR 19-39) days after symptom onset for all dermatologic manifestations and 27 (IQR 24-33) days after chilblains/pernio onset.

Like Hubiche *et al*, our data highlight the low frequency of SARS-CoV-2 PCR+ testing in COVID-19 patients with cutaneous manifestations. Positive predictive values for COVID-19 PCR are influenced by viral shedding kinetics, which are difficult to assess in non-respiratory presentations.<sup>4</sup> Our data reveal that early PCR testing is more likely to be positive than later testing, even when date-of-onset is defined by cutaneous manifestations rather than systemic symptoms.

Most COVID-19 antibody data are from systemically-ill patients; the kinetics of antibody production in mild-to-moderate COVID-19 infections remain unclear.<sup>5</sup> Here, positive antibodies resulted median 30 days from disease onset, beyond the frequently used 14-21 day testing window. In outpatients with true infection, many factors influence the likelihood of a positive antibody result: antibody production, test availability, assay sensitivity, and timing of care-seeking in relation to symptom-onset. These variables influence our interpretation of individual test results and our understanding of the association between pernio and COVID-19.

2

More population-level testing data is necessary to optimize diagnostic test timing. Positive identification of

COVID-19 in minimally-symptomatic patients, including patients with skin findings, is critical to the public health

effort.

Table 1: Distribution and timing of SARS-CoV-2 PCR and COVID-19 antibody test results in relation to

dermatologic manifestations.

	Chilblains/Pernio			All dermatologic conditions		
	Number of pernio patients	Number of pernio patients with timing data	Pernio onset to testing interval in days Median (IQR)	Number of patients	Number of patients with timing data	Dermatologic symptom onset to testing interval in days Median (IQR)
PCR Testing						
PCR+	23	5	8 (5-14)	208	67	6 (1-14)
PCR-	134	58	14 (7-28)	161	68	14 (7-24)
SARS-CoV-2 Positive Antibody Testing						
lgM+∖lgG+	-	-	-	1	1	14
lgM+∖lgG-	7	7	24 (23-28)	7	7	24 (23-28)
lgM-∖lgG+	1	1	99	6	6	32 (14-35)
IgM unknown \ IgG+	2	2	30 (25-35)	12	10	37 (25-40)
Ig+ (isotype unknown)	1	-	-	5	4	45 (20-84)
SARS-CoV-2 Negative Antibody Testing						
lgM-∖lgG-	17	5	37 (21-42)	18	5	37 (21-42)
IgM unknown \ IgG-	35	16	38 (33-50)	37	18	36 (28-49)
lg- (isotype unknown)	11	6	34 (21-60)	11	6	34 (21-60)

## **References:**

1. Hubiche T, Le Duff F, Chiaverini C, Giordanengo V, Passeron T. Negative SARS-CoV-2 PCR in patients with chilblain-like lesions. Lancet Infect Dis 2020.

2. Freeman EE, McMahon DE, Fitzgerald ME, Fox LP, Rosenbach M, Takeshita J et al. The AAD COVID-19

Registry: Crowdsourcing Dermatology in the Age of COVID-19. J Am Acad Dermatol 2020.

3. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR et al. The spectrum of COVID-19-

associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020.

Dermator 2020.

4. Sethuraman N, Jeremiah SS , Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA 2020.

5. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A et al. Convergent antibody responses to

SARS-CoV-2 in convalescent individuals. Nature 2020.